Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Lyell Immunopharma ( (LYEL) ) just unveiled an announcement.
On June 9, 2025, Lyell Immunopharma‘s Board of Directors expanded from seven to eight members, appointing Mark Bachleda, Pharm.D., M.B.A., as a Class I director. Dr. Bachleda will serve until the 2028 annual stockholders meeting, receiving compensation and equity grants as per the company’s policy, adjusted for a recent reverse stock split.
The most recent analyst rating on (LYEL) stock is a Hold with a $80.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.
Spark’s Take on LYEL Stock
According to Spark, TipRanks’ AI Analyst, LYEL is a Neutral.
The overall stock score is primarily impacted by financial challenges, including the inability to generate revenue and persistent operational losses. Despite positive technical indicators suggesting short-term bullish momentum, the company’s negative valuation metrics, such as the negative P/E ratio, weigh heavily on the score. The lack of earnings call data and corporate events means these components do not influence the score.
To see Spark’s full report on LYEL stock, click here.
More about Lyell Immunopharma
Lyell Immunopharma, Inc. operates in the biotechnology industry, focusing on developing innovative immunotherapies to treat cancer. The company is dedicated to enhancing the effectiveness of cell therapies for cancer treatment.
Average Trading Volume: 86,932
Technical Sentiment Signal: Sell
Current Market Cap: $189M
For an in-depth examination of LYEL stock, go to TipRanks’ Stock Analysis page.